Sentara Offers Newest Drug-Eluting Stent
Sentara.com
You have saved None as your preferred region Undo or Change Region
HR
Hampton Roads
Login for:
Search:
Go Search
Home News News Archives 2004 Archive

Sentara Offers Newest Drug-Eluting Stent 

Skip navigation links
Sentara News Home
Online Newsroom
News Archives
Sentara in the News

In early March the U.S. Food and Drug Administration (FDA) approved the next generation drug-eluting stent based on findings from the TAXUS IV study. Sentara is offering the latest stent to patients— Boston Scientific’s TAXUS™ Express2™.

Only the second drug-covered stent offered in the U.S., it is a familiar design but is covered with the drug paclitaxel, which is expected to further reduce reclogging of stented arteries.

Sentara physicians are currently enrolling patients in another national trial (Taxus V), whose findings may ultimately help offer TAXUS™ Express2™ to patients with small arteries, often women and diabetics, and those patients with long blockages. Finding of this 9-month trial may be available from Boston Scientific in fall 2004.

Contact Us
Get Social with Sentara Sentara on Facebook Sentara on Twitter Sentara on Flickr Sentara on FourSquare Sentara Today Blog Sentara on YouTube
Your community, not-for-profit health partner.
Copyright © 2014 Sentara Healthcare.
Contact Us   About Sentara Healthcare   Privacy Policy   User Agreement   Mobile Site